Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
about
The Candida albicans Histone Acetyltransferase Hat1 Regulates Stress Resistance and Virulence via Distinct Chromatin Assembly PathwaysCharacterization of a new clinical yeast species, Candida tunisiensis sp. nov., isolated from a strain collection from Tunisian hospitals.Fungemia in a Spanish hospital: the role of Candida parapsilosis over a 15-year period.Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011.Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey.Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillanAzole susceptibility and transcriptome profiling in Candida albicans mitochondrial electron transport chain complex I mutants.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study.Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference methodAntifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.Rapid identification of 6328 isolates of pathogenic yeasts using MALDI-ToF MS and a simplified, rapid extraction procedure that is compatible with the Bruker Biotyper platform and database.Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilutionAssessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom.Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility.Current concepts in laboratory testing to guide antimicrobial therapyIn vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.Michael A. Pfaller, M.D.Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogrLaboratory diagnostics of invasive fungal infections: an overview with emphasis on molecular approach.Voriconazole in clinical practice.The evolving role of antifungal susceptibility testing.The future of fungal susceptibility testing.Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of CandidaIn vitro susceptibility of environmental isolates of Exophiala dermatitidis to five antifungal drugs.Candida Bloodstream Infections in Italy: Changing Epidemiology during 16 Years of Surveillance.Antifungal Susceptibility Testing with Etest for Candida Species Isolated from Patients with Oral Candidiasis.Isolation and drug susceptibility of Candida parapsilosis sensu lato and other species of C. parapsilosis complex from patients with blood stream infections and proposal of a novel LAMP identification method for the species.The A395T mutation in ERG11 gene confers fluconazole resistance in Candida tropicalis causing candidemia.Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
P2860
Q28550375-09F5A7C5-92AC-40DE-BB95-483D34922228Q30573841-8522AAEB-BE1F-4CF1-9919-B24AE7324173Q30808061-46960BDF-C264-4AD0-BFA3-87318F401269Q30826889-75D23E5F-7A84-4844-A260-DD0CA19E07F5Q33798413-67523ACD-E44F-48D6-A0E0-E373EB9BA562Q34051921-6E28E8EC-E74C-41F8-958B-AC554C06C2E5Q34165039-CBCE567D-CFF0-4D00-A612-A2448B48196FQ34372192-C0D0CF9E-3F68-44F0-966D-0383A37AD06AQ34458142-6CB42460-F604-4215-A76D-4010FA275B9DQ34475368-5CE25F01-F795-4219-8B54-873B734D3166Q34505582-83554D3F-23FF-4DD2-899D-1E5304BD7A3BQ34586566-3256F616-4FCB-46A0-BF44-DAFEDC660F36Q35071660-990EF5A4-1B10-46E0-9394-53ADDE7B3795Q35487439-06F02454-8049-4DF4-BF4D-FC9B9B41974CQ35598950-72108B79-0C96-444F-9494-8B54A284C737Q35746090-CDCDF55D-CA31-49CE-90BC-2C317EEB6F83Q35847935-71D26B68-C082-4E76-BD30-07BDAE3445FDQ35867789-CFC59D17-BF86-4FCC-8350-B75A06917493Q36022956-0A903CDD-EE78-47EA-BAAE-D9AE508CD894Q36171475-5E927ED5-BFA1-461B-970E-AB486BEA4C07Q36172242-7AB53EDC-77EF-4B06-BF3B-5A65CE25A2A5Q36237993-5D219BA0-4BD2-445D-90FE-EA3CD2F56887Q36395704-D655C04D-07D5-49C7-9765-B70DFA3081E1Q36414000-D71DF982-FCDD-4042-B1AA-2D9DA6E02B6EQ36559020-0F0B179E-BE61-4F7C-BD50-BDEE93563F25Q36667530-25754A84-EF7D-483F-9B4D-0B7ADFEA9BFAQ36821803-46FB83F1-26E2-4C98-A89D-5CDBEF07F258Q36898053-6EEE8F2C-3C1E-468D-98BB-1163C95EC3F8Q37036246-44123962-655C-4CD8-BA4C-FE0CD5CA3DDCQ38008251-7B9D93DA-AD0F-4AE4-B187-E49213E87A89Q38061736-334E9FFF-A4F0-4482-BC09-FF889F5536F9Q38095809-7C0D32D3-54D5-4363-8FC4-FA3E4CDF9B83Q38258833-192E8D69-71B5-4E9E-92C6-EC5559556BC0Q38956082-C476A49C-EBD8-47F2-97B5-82E367B0AA0AQ39505421-8C6B4A62-3186-446E-ABC5-5385329B85DBQ40845928-0378D0D7-C70B-487B-96F3-374F28BD87D2Q41519513-C8E5EAF3-C18F-4805-A6A0-C775187315FFQ41613426-290E1BF5-8C62-490D-B404-EDC91F452ACEQ41660852-2AA42A88-982A-4792-A893-7641A77F7CEBQ42227869-CE7075DB-D443-4423-9010-0C588E215220
P2860
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Clinical breakpoints for voric ...... pecific interpretive criteria.
@ast
Clinical breakpoints for voric ...... pecific interpretive criteria.
@en
type
label
Clinical breakpoints for voric ...... pecific interpretive criteria.
@ast
Clinical breakpoints for voric ...... pecific interpretive criteria.
@en
prefLabel
Clinical breakpoints for voric ...... pecific interpretive criteria.
@ast
Clinical breakpoints for voric ...... pecific interpretive criteria.
@en
P2093
P1476
Clinical breakpoints for voric ...... pecific interpretive criteria.
@en
P2093
Ana Espinel-Ingroff
Barbara D Alexander
Cynthia C Knapp
Cynthia L Fowler
David Andes
Elizabeth M Johnson
Luis Ostrosky-Zeichner
Mahmoud A Ghannoum
Maiken C Arendrup
Mary R Motyl
P304
P356
10.1016/J.DIAGMICROBIO.2011.03.002
P577
2011-05-04T00:00:00Z